I would like to accept the invitation given to your readers to comment on "Selenium Compounds and the Prevention of Cancer: Research Needs and Public Health" (1) . Although I am such a firm believer in the protection selenium provides against certain cancers that I have been taking daily selenium yeast supple ments (100-400 jxg)for 4 years, I am perplexed by the selection of cancers to be studied in related doubleblind clinical trials, namely those of the liver, skin and esophagus.
In 1986, I published details of in excess of 13,000 correlations between the distributions of 219 environ mental variables and mortality from 66 specific cancers or groups of cancers in the United States (2) . Results clearly indicated fairly strong positive correlations (r > 0.4, P < 0.001) between reduced mortality from many specific cancers in both white and nonwhite males and females and high levels of selenium in both soils and fodder crops. In white men, for example, elevated soil selenium correlated postively with reduced mortality from cancer of the tongue, floor of the mouth, oral mesopharynx, esophagus, large intestine, rectum and bladder. At slightly lower levels of significance high selenium in soils was also linked with lowered death rates from cancer of the buccal cavity, lung and phar ynx. In addition to many similar apparent associations in both white and nonwhite women, mortality from cancers of the breast and ovary was also strongly neg atively correlated with high levels of soil selenium. This element, therefore, appears linked to reduced death rates from cancers of the digestive and respiratory tracts and the female reproductive system. If this suggestion is correct one might logically anticipate that selenium supplements (especially if given together with calcium and vitamin E) would reduce the incidence of cancer of the esophagus.
However, the other two cancers (liver and skin) se lected for double-blind testing with selenium (1) dem onstrate very poor spatial associations with the distri bution of this element. In the U.S., mortality from cancer of the liver is generally highest where soils are partic ularly enriched in magnesium, calcium, phosphorus and potassium, whereas the death rate from nonmelanoma skin cancer is greatest where soils are very depleted in these elements.
Mortality distribution patterns in the United States and elsewhere (2)tend to suggest that cancers (with the exception of the lymphomas and leukemias) are most common in populations exposed to both industrial car cinogens and dietary bulk and trace element imbal ances. The organ at risk seems to vary with the im balance involved. Calcium, for example, appears protective against cancers of the mouth and esophagus, while simultaneously promoting cancer of the liver.
In conclusion, I would like to suggest to the medical profession that women who have recently undergone mastectomies would be ideal participants in trials to test the effectiveness of selenium as a cancer chemopreventative. This is because epidemiological and clin ical evidence both suggest that selenium is protective against breast cancer in white and nonwhite (Black and Oriental) women (2, 3), whereas adjuvant chemother apy with multiple agents (4)only increases their 3-year survival rate by 4% (Â±3.5%).
